Skip to content

By continuing to use this site, you agree to our use of cookies as described in our Cookie Policy.

About “Good On” time
How CREXONT works
Starting CREXONT
Safety
Support & resources
CREXONT stories
En español
Stay updated
Important Safety Information
Full Prescribing Information
For Healthcare Providers
Stay updated

About “Good On” time
How CREXONT works
Starting CREXONT
Safety
Support & resources
CREXONT stories
En español
Stay updated
Important Safety Information
Full Prescribing Information
For Healthcare Providers
Stay updated

Acerca del tiempo en estado “Good On”
Cómo actúa CREXONT
Iniciar el tratamiento con CREXONT
Seguridad
Apoyo y recursos
Historias de CREXONT
En español
Manténgase informado
Información importante de seguridad
Información completa de prescripción
Para proveedores de atención médica
Manténgase informado

Acerca del tiempo en estado “Good On”
Cómo actúa CREXONT
Iniciar el tratamiento con CREXONT
Seguridad
Apoyo y recursos
Historias de CREXONT
En español
Manténgase informado
Información importante de seguridad
Información completa de prescripción
Para proveedores de atención médica
Manténgase informado

For Healthcare Providers
Important Safety Information
Full Prescribing Information
En español
Stay updated

For Healthcare Providers
Important Safety Information
Full Prescribing Information
En español
Stay updated

About “Good On” time
How CREXONT works
Starting CREXONT
Safety
Support & resources
Patient stories

About “Good On” time
How CREXONT works
Starting CREXONT
Safety
Support & resources
Patient stories

Sitemap

<span data-metadata="">
<span data-metadata=""><span data-buffer="">
Sitemap

Pages

Home
About “Good On” time
How CREXONT works
Starting CREXONT
Safety
Support & resources
Stay updated
CREXONT stories
Home Spanish

Indication & Important Safety Information

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.

Your doctor should evaluate vitamin B6 levels before and during treatment with carbidopa/levodopa therapies as seizures associated with low levels of vitamin B6 have been reported. Traditional anti-seizure medications were not effective, and seizures were only resolved after vitamin B6 administration. Other symptoms of vitamin B6 deficiency include depression, confusion, cracked corners of the mouth, swollen tongue, skin inflammation, low red blood cell count, and/or numbness, tingling, or weakness in the extremities. Your doctor may advise you to take vitamin B6 as necessary.

The most common side effects that may occur with CREXONT are nausea and anxiety.

It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.

Swallow CREXONT whole. Do not chew, divide, or crush the capsules.

Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
Experience hallucinations or abnormal thoughts and behaviors
Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
Have thoughts of suicide or have attempted suicide
Have abnormal involuntary movements that appear or get worse during treatment
Have ever had a peptic ulcer or glaucoma
Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
Are breastfeeding during therapy

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Global Patient Safety at 1-877- 835-5472, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information talk to your healthcare provider.

Indication & Important Safety Information

INDICATION

CREXONT® (carbidopa and levodopa) extended-release capsules is a prescription medication for the treatment of Parkinson’s disease, Parkinson’s disease caused by infection or inflammation of the brain, or Parkinson’s disease-like symptoms that may result from carbon monoxide or manganese poisoning in adults.

IMPORTANT SAFETY INFORMATION

Do not take CREXONT with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors.

Do not take CREXONT with other carbidopa-levodopa preparations without consulting your healthcare provider.

CREXONT may cause falling asleep during activities of daily living, somnolence, or dizziness. Avoid activities that require alertness such as driving and operating machinery until you know how CREXONT affects you.

Your doctor should evaluate vitamin B6 levels before and during treatment with carbidopa/levodopa therapies as seizures associated with low levels of vitamin B6 have been reported. Traditional anti-seizure medications were not effective, and seizures were only resolved after vitamin B6 administration. Other symptoms of vitamin B6 deficiency include depression, confusion, cracked corners of the mouth, swollen tongue, skin inflammation, low red blood cell count, and/or numbness, tingling, or weakness in the extremities. Your doctor may advise you to take vitamin B6 as necessary.

The most common side effects that may occur with CREXONT are nausea and anxiety.

It is important to avoid sudden discontinuation or rapid dose reduction of CREXONT. If you are discontinuing CREXONT, work with your healthcare provider to taper the dose over time to reduce the risk of fever or confusion.

You may take CREXONT with or without food, but taking it with food may decrease or delay its effect. Consider taking the first dose of the day about 1 to 2 hours before eating.

Swallow CREXONT whole. Do not chew, divide, or crush the capsules.

Do not take CREXONT with alcohol.

Tell your healthcare provider if you:

Have any heart conditions, especially if you have had a heart attack or irregular heartbeats
Experience hallucinations or abnormal thoughts and behaviors
Have an inability to control urges to gamble, have increased sexual urges, or experience other intense urges
Have thoughts of suicide or have attempted suicide
Have abnormal involuntary movements that appear or get worse during treatment
Have ever had a peptic ulcer or glaucoma
Become or intend to become pregnant. Based on animal data, CREXONT may cause fetal harm
Are breastfeeding during therapy

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Global Patient Safety at 1-877- 835-5472, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information. For more information talk to your healthcare provider.

About “Good On” time
How CREXONT works
Starting CREXONT
Safety
Support & resources
CREXONT stories

About “Good On” time
How CREXONT works
Starting CREXONT
Safety
Support & resources
CREXONT stories

En español
Stay updated
Sitemap
Thriving with PD

En español
Stay updated
Sitemap
Thriving with PD

Terms of use
Privacy notice
Contact us
Accessibility statement
Cookie policy

Terms of use
Privacy notice
Contact us
Accessibility statement
Cookie policy

Amneal_rgb_k (4)

CREXONT® is a registered trademark of Amneal Pharmaceuticals LLC. © 2026 Amneal Pharmaceuticals LLC.

Distributed by Amneal Specialty, a division of Amneal Pharmaceuticals LLC.

All rights reserved. PP-IPX203-US-0026 05/2026

This is intended for residents of the United States only. Any product discussed herein may have different product labeling in different countries. Please read the full Prescribing Information and discuss it with your doctor or healthcare professional.

Está a punto de abandonar nuestro sitio.

Este enlace lo dirigirá a una página externa, administrada por un tercero independiente, que no está sujeto a nuestra Política de privacidad.

¿Confirma que desea continuar?

You are now leaving this site

This link will take you to a different site that is owned and operated by an independent third party to which the Privacy Policy does not apply.

Are you sure you want to continue?